Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 3
1954 1
1955 1
1956 6
1957 8
1958 14
1959 5
1961 3
1964 3
1967 6
1970 4
1971 1
1972 2
1973 3
1974 4
1975 7
1976 1
1977 1
1978 1
1979 3
1980 3
1981 1
1982 6
1983 5
1984 12
1985 12
1986 8
1987 5
1988 4
1989 24
1990 17
1991 8
1992 4
1993 9
1994 1
1995 7
1996 8
1997 14
1998 16
1999 18
2000 11
2001 11
2002 6
2003 5
2004 5
2005 2
2006 6
2007 9
2008 9
2009 6
2010 5
2011 4
2012 5
2013 5
2014 8
2015 9
2016 8
2017 7
2018 15
2019 18
2020 10
2021 10
2022 9
2023 15
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

449 results

Results by year

Filters applied: . Clear all
Page 1
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL. Kappos L, et al. Among authors: bernasconi c. JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. JAMA Neurol. 2020. PMID: 32511687 Free PMC article. Clinical Trial.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE. Bar-Or A, et al. Among authors: bernasconi c. EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22. EBioMedicine. 2023. PMID: 37354600 Free PMC article. Clinical Trial.
Metabolites in the regulatory risk assessment of pesticides in the EU.
Pelkonen O, Abass K, Parra Morte JM, Panzarea M, Testai E, Rudaz S, Louisse J, Gundert-Remy U, Wolterink G, Jean-Lou Cm D, Coecke S, Bernasconi C. Pelkonen O, et al. Among authors: bernasconi c. Front Toxicol. 2023 Dec 19;5:1304885. doi: 10.3389/ftox.2023.1304885. eCollection 2023. Front Toxicol. 2023. PMID: 38188093 Free PMC article. Review.
Practical Aspects of Designing and Conducting Validation Studies Involving Multi-study Trials.
Coecke S, Bernasconi C, Bowe G, Bostroem AC, Burton J, Cole T, Fortaner S, Gouliarmou V, Gray A, Griesinger C, Louhimies S, Gyves EM, Joossens E, Prinz MJ, Milcamps A, Parissis N, Wilk-Zasadna I, Barroso J, Desprez B, Langezaal I, Liska R, Morath S, Reina V, Zorzoli C, Zuang V. Coecke S, et al. Among authors: bernasconi c. Adv Exp Med Biol. 2016;856:133-163. doi: 10.1007/978-3-319-33826-2_5. Adv Exp Med Biol. 2016. PMID: 27671721 Review.
Frequency and evolution of sleep-wake disturbances after ischemic stroke: A 2-year prospective study of 437 patients.
Duss SB, Bauer-Gambelli SA, Bernasconi C, Dekkers MPJ, Gorban-Peric C, Kuen D, Seiler A, Oberholzer M, Alexiev F, Lippert J, Brill AK, Ott SR, Zubler F, Horvath T, Schmidt MH, Manconi M, Bassetti CLA. Duss SB, et al. Among authors: bernasconi c. Sleep Med. 2023 Jan;101:244-251. doi: 10.1016/j.sleep.2022.10.007. Epub 2022 Oct 22. Sleep Med. 2023. PMID: 36446142 Free article.
449 results